20/20 Biolabs receives Nasdaq bid-price deficiency notice, has 180 days to cure
20/20 Biolabs received written notification from Nasdaq on July 17, 2026, that it failed to maintain the $1.00 minimum closing bid price for 30 consecutive business days from June 3 to July 16, 2026. The company has been granted a 180-calendar day compliance period ending January 13, 2027, to regain compliance by achieving a closing bid price of at least $1.00 for at least ten consecutive business days. On the same day, the company entered into a standstill agreement with Streeterville Capital, LLC, restricting Streeterville's conversion of its Series E preferred stock for 120 days unless the common stock trades at least 10% above the Nasdaq Minimum Price.
- Nasdaq minimum closing bid price deficiency for 30 consecutive business days from June 3, 2026 to July 16, 2026
- 180-calendar day compliance period ending January 13, 2027
- Standstill agreement effective July 16, 2026, between Streeterville Capital, LLC and 20/20 Biolabs restricting conversion of Series E shares for 120 days
- Series E convertible preferred stock issued pursuant to November 17, 2025 securities purchase agreement for up to $40,000,000
- Conversion price equal to lower of $11.42 and 89% of lowest daily volume weighted average price during ten trading day period prior to conversion
- Standstill terminates immediately upon breach or any Event of Default under Certificate of Designation
20/20 Biolabs faces potential delisting if it cannot restore its stock price above $1.00 per share within the next six months, while simultaneously managing a major convertible preferred holder whose ability to convert has been temporarily restricted pending stock price recovery.
- NT 10-Q
- 8-Kthis filing
Derived from 8-K filed 2026-07-22. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →